COMPARATIVE ANALYSIS OF CYTOMEGALOVIRUS REACTIVATION AFTER HAPLOIDENTICAL VS MATCHED SIBLING DONOR ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION (EBMT 2026) - Mar 14, 2026 - Abstract #B130; Pres time: Mar 24, 2026; 06:00 PM - 07:00 PM; Location: VELAZQUEZ; "GVHD prophylaxis consisted of cyclosporine plus methotrexate for MSD transplants, and post-transplant cyclophosphamide on days +3/+4 followed by cyclosporine and mycophenolate for haploidentical HSCT...No patient received letermovir prophylaxis, as it only became available in Mexico after 2025... CMV reactivation was significantly more frequent after haploidentical transplantation, although the timing of reactivation and CMV-related clinical presentation were similar across donor types. Overall survival did not differ according to donor type; however, CMV reactivation was associated with inferior long-term survival. These findings suggest that CMV reactivation represents a clinically relevant event influencing outcomes after allogeneic hematopoietic stem cell transplantation, beyond donor type alone"
Acute Lymphocytic Leukemia • Acute Myelogenous Leukemia • Bone Marrow Transplantation • Cytomegalovirus Infection • Graft versus Host Disease • Hematological Malignancies • Immunology • Infectious Disease • Leukemia • Pneumonia • Respiratory Diseases • Transplantation
|
|
Marco Alejandro Jiménez-Ochoa1; María Margarita Contreras-Serratos1; Carlos Daniel Reyes-Morales1
|